Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Addex Stops Parkinson's-Associated Dyskinesia Trial - Read Here Why

  • Addex Therapeutics Ltd (NASDAQ:ADXN) has terminated the Phase 2b/3 study of dipraglurant for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow recruitment of patients. 
  • Data readout from the trial was expected in 1H of 2023.
  • The company attributes this to the consequences of COVID-19-related patient concerns about participation in studies, staffing shortages, and turnover within study sites.
  • The company plans to advance its preclinical portfolio toward the clinic and pursue strategic collaborations for selected programs. 
  • Concurrently the company is also focusing on delivering under its strategic partnership with Indivior. 
  • Addex's partner, Janssen, a unit of Johnson & Johnson (NYSE:JNJ), is also expected to deliver data from the Phase 2 study of ADX71149 in epilepsy patients in Q4 of 2022.
  • Last month, Addex announced that the outcome of a small Phase 2a feasibility study of dipraglurant in patients with blepharospasm was inconclusive and did not meet all of its objectives
  • There were no safety concerns.
  • In light of the company's termination of the dipraglurant program for PD-LID, the company is suspending the company's financial guidance.
  • Price Action: ADXN shares are 39.9% at $2.01 during the premarket session on the last check Friday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.